# Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy

> **NCT02806752** · PHASE4 · UNKNOWN · sponsor: **Aier School of Ophthalmology, Central South University** · enrollment: 120 (estimated)

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** Triamcinolone Acetonide
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02806752
- **Lead sponsor:** Aier School of Ophthalmology, Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2018-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02806752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02806752, "Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02806752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*